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Sodium nitrate co‑supplementation 
does not exacerbate low dose 
metronomic doxorubicin‑induced 
cachexia in healthy mice
Dean G. campelj1,2, Danielle A. Debruin1,2, Cara A. Timpani1,2, Alan Hayes1,2,3, 
Craig A. Goodman2,4 & emma Rybalka1,2*
The purpose of this study was to determine whether (1) sodium nitrate (SN) treatment progressed 
or alleviated doxorubicin (DOX)-induced cachexia and muscle wasting; and (2) if a more-clinically 
relevant low-dose metronomic (LDM) DOX treatment regimen compared to the high dosage bolus 
commonly used in animal research, was sufficient to induce cachexia in mice. Six-week old male 
Balb/C mice (n = 16) were treated with three intraperitoneal injections of either vehicle (0.9% NaCl; 
VEH) or DOX (4 mg/kg) over one week. To test the hypothesis that sodium nitrate treatment could 
protect against DOX-induced symptomology, a group of mice (n = 8) were treated with 1 mM  NaNO3 in 
drinking water during DOX (4 mg/kg) treatment (DOX + SN). Body composition indices were assessed 
using echoMRI scanning, whilst physical and metabolic activity were assessed via indirect calorimetry, 
before and after the treatment regimen. Skeletal and cardiac muscles were excised to investigate 
histological and molecular parameters. LDM DOX treatment induced cachexia with significant impacts 
on both body and lean mass, and fatigue/malaise (i.e. it reduced voluntary wheel running and energy 
expenditure) that was associated with oxidative/nitrostative stress sufficient to induce the molecular 
cytotoxic stress regulator, nuclear factor erythroid-2-related factor 2 (NRF-2). SN co-treatment 
afforded no therapeutic potential, nor did it promote the wasting of lean tissue. Our data re-affirm 
a cardioprotective effect for SN against DOX-induced collagen deposition. In our mouse model, SN 
protected against LDM DOX-induced cardiac fibrosis but had no effect on cachexia at the conclusion of 
the regimen.
Anthracyclines are a class of chemotherapeutic agents that are currently utilized as treatments for multiple 
cancers due to their potent anti-cancer  efficacy1. One of the most common anthracyclines in clinical use is 
doxorubicin (DOX), which inhibits topoisomerase-II, leading to DNA damage and cell cycle  arrest2. DOX also 
promotes toxicity through the reduction of its quinone moiety to an unstable semiquinone, during its metabo-
lism by NADH dehydrogenase/Complex I of the mitochondrial ETC. In this setting, it hijacks homeostatic 
redox cycling to induce formation of superoxide  (O2-) anion radicals and subsequently increases production of 
reactive oxygen species (ROS) leading to oxidative  damage3. Despite the robust anti-cancer effectivity of DOX, 
its staunch cytotoxic profile promotes non-specific, off-target effects in healthy tissue (in particular cardiac and 
skeletal muscle; for extensive reviews  see4,5, respectively) limiting its clinical utility and increasing the risk of 
morbidity and  mortality6. As such, there is warranted clinical interest in preserving cardiac and skeletal muscle 
health during DOX administration, and a variety of adjunct therapeutics have been purported to attenuate the 
negative side-effects of DOX on these tissues.
Of clinical interest, a potential therapeutic strategy to protect against DOX-induced cardiotoxicity is sodium 
nitrate (SN) co-supplementation. SN acts by augmenting the nitrate/nitrite/nitric oxide (NO) pathway via a 
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nitric oxide synthase (NOS)-independent mechanism, to increase NO  production7,8. Importantly, this strategy 
has been shown to have therapeutic cardioprotective effects in other pre-clinical models of  cardiomyopathy9–14. 
Pertinent to DOX-induced cardiomyopathy, two foundational studies have been conducted exploring the car-
dioprotective potential of SN co-supplementation. Data has demonstrated benefits to left ventricular function 
secondary to promoting anti-oxidant activity, and reducing oxidative stress via the inhibition of lipid peroxida-
tion and amelioration of mitochondrial Complex I  dysfunction15,16. Despite the strong cardioprotective efficacy 
of SN co-supplementation against DOX-induced cardiotoxicity, it is currently unclear as to whether SN co-
supplementation elicits protective effects against the skeletal muscle toxicity induced by DOX.
DOX-induced skeletal muscle toxicity is widely accepted to be a consequence of its metabolism at Complex 
I of the mitochondrial ETC, resulting in mitochondrial dysfunction secondary to the enhancement of oxida-
tive stress. As a consequence, DOX treatment is associated with skeletal muscle atrophy/wasting, as well as 
functional  deficits17–25 as characterized by reduced force production and increased susceptibility to skeletal 
muscle fatigue in pre-clinical animal  models26–29. These data are consistent with clinical descriptions of exer-
cise intolerance, a lesser capacity for activities of daily living and reduced quality of life in patients following 
chemotherapy  treatment30–32. The functional benefits of SN co-supplementation on the skeletal muscular system 
in both rodents and humans is well documented, whereby enhanced NO bioavailability augments functional 
adaptations that lower the oxidative cost of exercise, subsequently improving fatigue resistance and exercise 
 tolerance33–35. However, in skeletal myopathic conditions, SN co-supplementation has equivocally been shown 
to enhance  myopathy36,37. In a pro-oxidant setting, akin to that induced by DOX administration, enhancing the 
bioavailability of NO alongside superfluous superoxide anions driven by DOX metabolism leads to peroxynitrite 
formation and the exacerbation of nitrostative  stress38.Thus, an aim of this study was to determine whether SN 
co-supplementation could afford the same therapeutic benefit as that observed previously against DOX-induced 
cardiotoxicity, or whether SN co-supplementation would exacerbate myopathy as per our previous study in the 
mdx mouse model of Duchenne Muscular  Dystrophy37.
A second aim of this study was to investigate the effects of low-dose, metronomic (LDM) DOX administration 
on skeletal and cardiac muscle. A current problem with pre-clinical research using rodent models to investigate 
DOX-induced toxicity surrounds the administration of a single maximum tolerable dose (MTD) injection of 
DOX to induce a severe scenario of toxicity and  mortality39. This largely misrepresents the clinical scenario, 
in which DOX is administered repeatedly at a fractional dosage over a set time-course, to give a cumulative 
dose equivalent to the MTD. Recently, there has been interest in the LDM administration of chemotherapeutic 
agents to reduce systemic toxicity, whilst maintaining the anti-cancer efficacy of  treatment40,41. Remarkably, there 
is few data derived from animal studies using LDM DOX administration to investigate potential therapeutic 
adjuncts against DOX-induced side-effects. As such, the clinical applicability of experimental adjuvants is largely 
unknown. In this study we utilized a murine model of LDM administration of DOX in an attempt to reduce the 
severe toxicity profile associated with the MTD model, whilst still being able to make insights into DOX-induced 
cardiac and skeletal muscle toxicity. Furthermore, utilizing a LDM model of DOX administration allows for a 
more translatable screening of potential therapeutic strategies to protect against the negative side-effects elicited 
to cardiac and skeletal muscle from DOX.
Figure 1.  The effect of LDM DOX administration and SN co-supplementation on body mass and composition 
indices, muscle and organ mass. (A) Body mass was measured throughout the experimental timeline and 
repeated measures analysis performed. A 5% increase in body mass was observed between day 1 and 3 in the 
VEH mice (*p < 0.05), which was inhibited by DOX such that by day 3, both DOX and DOX + SN mice had 
a lower body mass compared to VEH (*p < 0.05). Body mass was stable from day 3 to 7 in VEH mice, but 
declined steadily with DOX treatment from day 5 (*p < 0.05) and DOX + SN treatment from day 3 (*p < 0.05). 
As such the body mass of DOX and DOX + SN mice was lower compared to VEH at day 5 and 7 (*p < 0.05). 
Weight loss during this period was actually exacerbated by SN supplementation (^p < 0.05 DOX + SN versus 
DOX). Body mass declined during the 24 h metabolic cage stay between day 7 and 8 in VEH mice (*p < 0.05) 
due to participation in voluntary wheel running. Exercise-induced weight loss was not observed in DOX and 
DOX + SN mice (since they did not run as far as VEH mice) albeit body mass was still lower for these groups 
compared to VEH mice (*p < 0.05). (B) As defined by a > 5% reduction in body mass displacement relative to 
the VEH, LDM DOX and DOX + SN treatment induced cachexia (*^p < 0.05). Mirroring body mass changes, 
both (C) lean and (D) fat mass was significantly lower in DOX and DOX + SN mice compared to VEH mice 
(*p < 0.05). (E) The mass of extensor digitorum longus (EDL), soleus (SOL), plantaris (PLNT) and tibialis 
anterior (TA) muscles was significantly reduced by DOX administered alone and in the DOX + SN treatment 
compared to VEH mice (*p < 0.05). However, when (F) muscle mass was corrected for final body mass (BM), 
there was no treatment effect observed. Like muscles, organ mass was either lower, or trended to be lower 
following DOX treatment either alone or in the DOX + SN treatment for each of (G) spleen (SPLN; *p < 0.05 for 
DOX and DOX + SN compared to VEH), kidneys (KIDS; p = 0.07 DOX versus VEH and *p < 0.05 DOX + SN 
versus VEH), fat (epididymal and subcutaneous; FAT; *p < 0.05 for DOX versus VEH and p = 0.05 for DOX + SN 
versus VEH) and liver (LIV; *p < 0.05 for DOX and DOX + SN versus VEH). (H) When corrected for final BM, 
DOX treatment showed specific targeting of both SPLN (*p < 0.05 for both DOX and DOX + SN versus VEH) 
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Results
Assessment of body composition indices, muscle and organ mass. We found that LDM DOX 
administration induced growth inhibition initially (i.e. from day 1–5), which progressively led to a loss of body 
mass from day 5 to 7 (p < 0.05 DOX and DOX + SN different from VEH; Fig. 1A & Supp Fig. 1) that was exacer-
bated by SN supplementation (p < 0.05 DOX + SN from DOX; Fig. 1A and Supp Fig. 1). Whereas VEH mice lost 
body mass during the 24 h spent (i.e. from day 7 to 8) in the metabolic cages with access to running wheels, DOX 
and DOX + SN treated mice did not (Fig. 1A). By the experimental endpoint at day 8, DOX-treated mice were 
cachetic (p < 0.05; Fig. 1B), but cachexia was neither exacerbated nor alleviated by SN treatment (i.e. DOX and 
DOX + SN mice were comparable in the degree of body weight displacement from VEH mice; Fig. 1B). Unsur-
prisingly, DOX-induced cachexia was mirrored in body composition indices measured via PRE- and POST-
treatment echoMRI scans. DOX administration induced significant lean and fat mass loss which could not be 
rescued by SN co-supplementation (p < 0.05; Fig. 1C, D & Supp Fig. 1). Interestingly, while this wasting pheno-
type was characterised by both the loss of raw skeletal muscle mass (p < 0.01; Fig. 1E) and organ mass (p < 0.0001; 
Fig. 1G), skeletal muscle mass (Fig. 1F) was not a specific target of DOX like some organs were (Fig. 1H) with 
spleen and fat mass being the only tissues to waste disproportionately to body mass (p < 0.05; Fig. 1H). There 
was no significant effect of SN co-supplementation on any measure of muscle or organ mass relative to DOX 
treatment alone (Fig. 1E–H). Our data highlight that LDM DOX administration induces a wasting phenotype 
that broadly impacts the skeletal muscles, adipose tissue and organs, but which specifically wastes the spleen and 
adipose tissue, which is neither rescued nor exacerbated by SN co-supplementation.
Assessment of ambulatory and metabolic activity via indirect calorimetry. DOX treatment has 
been previously shown to induce exercise intolerance in cancer  patients30, while dietary nitrate supplementa-
tion is a potentiator of exercise performance in healthy  humans42. Thus, in this study, we assessed the effects of 
LDM DOX and DOX + SN treatment on voluntary physical and metabolic activity over a 24 h period in mice. 
There was a strong trend for LDM DOX treatment to reduce wheel running activity between the PRE and 
POST periods compared to VEH (p = 0.08; Fig. 2A,B) and this effect was significant in the DOX + SN group 
(p < 0.05; Fig. 2A,B). The reduction in voluntary wheel running activity was concomitant with reduced energy 
expenditure in the PRE to POST treatment periods (p < 0.05; Fig. 2A,C), which was interesting because the PRE-
treatment energy expenditure of this particular cohort of mice was significantly higher than that of the VEH and 
DOX + SN groups (p < 0.05 for both; Fig. 2A). The DOX-induced reduction in energy expenditure was associated 
with reduced wheel-running activity (p < 0.05; Fig. 2B) rather than changes to metabolism, as reflected by the 
RQ (Fig. 2D), and thus, is likely comparable to mental and physical fatigue reported by human patients during 
chemotherapy  treatment43 rather than true physiological fatigue. SN co-supplementation had no effect on the 
DOX-induced changes in energy expenditure (Fig. 2A), but it did elevate the RQ compared to VEH (p,0.05; 
Fig. 2D) and there was a trend toward the same effect compared to DOX treatment alone (p = 0.09; Fig. 2D), 
suggestive of increased dependency on glucose as a substrate during activity.
Assessment of cardiac muscle mass and histology. Cardiotoxicity is a well-established side-effect 
of DOX treatment and severity is dose-dependent44. In our study, LDM DOX administration had no effect on 
heart mass (Fig.  3A,B), while SN co-supplementation reduced raw heart mass (p < 0.05, Fig.  3A), albeit this 
was not significant when normalised to body mass (Fig. 3B). We investigated histological changes induced by 
chemotherapy, with LDM DOX administration increasing the total diameter of the heart (p < 0.05; Fig. 3C). 
Interestingly, there were no significant effects elicited from LDM DOX administration on morphological cardiac 
muscle indices (Fig. 3D). LDM DOX administration did, however, increase collagen deposition in cardiac tissue 
(Fig. 3E), suggestive of early-stage myocardial fibrosis that would likely reduce the contractility of the  heart45,46. 
SN has demonstrable therapeutic benefit in mitigating DOX-induced cardiotoxicity in mice when supplemented 
prior to, and following, the administration of a single MTD bolus of  DOX15. In our study, DOX + SN treatment 
actually enhanced the DOX-induced reduction in heart mass (Fig. 3A), however, this appeared to be related to 
the larger body mass reduction observed with DOX + SN versus DOX-treatment alone since this effect was abol-
ished when heart mass was normalised to body weight (Fig. 3B). We did observe a strong trend for DOX + SN 
treatment to mitigate the enlarged total heart diameter induced by DOX-treatment (p = 0.08; Fig. 3C), and this is 
likely related to the beneficial effect that SN co-supplementation had on collagen deposition through the cardiac 
tissue, in which collagen content was reduced compared to both DOX and VEH mice (p < 0.05; Fig. 3E). Interest-
ingly, SN co-supplementation increased LV wall thickness compared to both VEH and DOX treatment (p < 0.05; 
Fig. 3D), however it significantly reduced the LV and RV lumen diameter (p < 0.05 DOX + SN versus VEH and 
DOX; Fig. 3D). Overall, our data suggest that SN co-supplementation has protective effects against a mild pro-
collagenic driven cardiofibrosis induced by LDM DOX treatment, which may be related to the smaller heart size.
Assessment of skeletal muscle histology. Neither DOX administration, nor SN co-supplementation, 
had a significant effect on the fibre CSA or skeletal muscle architecture of the TA when stained with H&E 
(Fig. 4A & B). Furthermore, there was no change in fat deposition, measured via ORO staining (Fig. 4C), nor 
mitochondrial abundance/activity, as indicated by SDH staining (Fig.  4D) from DOX administration or SN 
co-supplementation. To determine whether there were differential effects of DOX with and without SN co-
supplementation on oxidative versus glycolytic fibres, we conducted CSA analysis on distinct populations of 
these fibre types based upon SDH staining intensity. There was no effect of DOX on the CSA of either oxidative 
or glycolytic fibres (Fig. 4E). DOX + SN treatment significantly reduced the CSA of glycolytic fibres (p < 0.05 
DOX + SN versus VEH; p = 0.07 DOX + SN versus DOX; Fig. 4E) but had no effect on oxidative fibres, suggestive 
of nitrate-mediated fibre type transformation from IIb to IIa type.
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Assessment of molecular redox signalling pathways in skeletal muscle. Metabolised by Com-
plex I of the mitochondrial ETC, DOX is a well-known inducer of superoxide production as a by-product of its 
 metabolism4,5,13. Similarly, we have previously demonstrated that in a pro-oxidant environment, SN co-supple-
mentation has a damaging effect on skeletal muscle secondary to a higher peroxynitrite  production37. Thus, we 
next investigated whether oxidative or nitrostative stress played a role in the DOX-induced reduction in energy 
expenditure. Interestingly, there was no effect of LDM DOX administration on 4-hydroxy-2-nonenal (4-HNE; 
Fig. 5A,J), a marker of lipid peroxidation. However, there was a significant increase in nitrotyrosine (p < 0.05; 
Figure 2.  The effect of LDM DOX administration and SN co-supplementation on ambulatory and metabolic 
activity. (A) Data are displayed for ambulatory (wheel and cage meters) and metabolic activity (energy 
expenditure and respiratory quotient (RQ) parameters over 24 h in each of the PRE and POST treatment 
periods. (B) There was a strong trend for DOX to increase wheel running activity and a significant effect of 
DOX + SN treatment on wheel running activity in the PRE to POST treatment periods, (C) This was mirrored 
by significant reductions in energy expenditure between the PRE and POST treatment periods for both DOX 
and DOX + SN (*^p < 0.05). (D) While there was no effect of DOX on the respiratory quotient (RQ), DOX + SN 
significantly increased the RQ in favour of glucose as an energy substrate compared to VEH (*p < 0.05) and there 
was a strong trend for the same effect compared to DOX treatment alone (p = 0.09); n = 5–7 per group.
6
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Fig. 5B,J), a marker of excessive peroxynitrite  (ONOO-) production. Surprisingly, SN co-supplementation did 
not augment the DOX-induced increase in nitrotyrosine expression (p < 0.05; Fig. 5B,J). LDM DOX adminis-
tration also significantly increased the expression of the redox status sensor, nuclear factor erythroid-2-related 
factor 2 (NRF-2; p < 0.05; Fig. 5C,J), and this was unchanged by SN co-supplementation. Since NRF-2 is the mas-
ter regulator of the anti-oxidant response to cellular  stress47, we wanted to investigate changes to regulators or 
downstream targets of NRF-2. The protein expression of the negative regulator of NRF-2, Keap-1 (Fig. 5D,J), nor 
the serine 349 residue on p62 (Fig. 5E,J), which plays a role in balancing the NRF-2 and Keap-1 interaction, did 
not alter in response to LDM DOX administration. Interestingly, we were able to demonstrate that LDM DOX 
administration significantly upregulated DJ-1 protein expression, which is a positive regulator of NRF-2 activa-
tion through enhancing NRF-2 stability and reducing ubiquitination and Keap-1 dependent  degradation48,49, but 
not when co-supplemented with SN (p < 0.05; Fig. 5F,J). The protein expression of anti-oxidant enzymes that are 
transcriptional targets of NRF-2, being NAD(P)H dehydrogenase quinone-1 (NQO-1), superoxide dismutase-1 
(SOD-1) and heme oxygenase-1 (HO-1) (Fig. 5G-J), were not altered by LDM DOX administration nor SN co-
supplementation.
Assessment of molecular mitochondrial content signalling in skeletal muscle. In light of the 
observation that administration of the LDM DOX regimen increased NRF-2 protein expression in skeletal mus-
cle of mice with and without SN co-supplementation, and NRF-2 can modulate mitochondrial function and 
maintenance, we wanted to investigate whether molecular markers of mitochondrial content and remodelling 
were also affected. While we saw a trend for DOX to increase citrate synthase (CS) activity (p = 0.097; Fig. 6A), 
the gold standard marker of mitochondrial  content50 , there was no change to the protein expression of Complex 
I, II, IV and V from treatment groups (Fig. 6B, F) suggesting unchanged mitochondrial content. However, there 
was a strong trend for LDM DOX administration (p = 0.07; Fig. 6B) to reduce Complex III protein expression, 
whilst DOX + SN treatment did significantly reduce Complex III protein expression (p < 0.05; Fig. 6B, F). To 
assess damage to the mitochondrial pool, we also probed for cytochrome C (Cyt-c), which was significantly 
increased by both LDM DOX and DOX + SN treatment (p < 0.05, Fig. 6C, F). Following on from this finding we 
wanted to investigate if there were any effects on molecular markers of mitochondrial remodelling and stress, 
hence we probed for a member of the PGC-1 family (PGC-1β) and activation (phosphorylation) of adenosine 
monophosphate-activated protein kinase (AMPK). PGC-1β was significantly increased from LDM DOX admin-
istration (p < 0.05, Fig. 6D,F) but was normalised to VEH control levels by SN co-supplementation (p < 0.05, 
Fig. 6D,F). AMPK activation was unaffected by DOX treatment but was significantly increased by SN supple-
mentation (p < 0.05; Fig. 6E,F).
Discussion
The major findings in this study are that the LDM DOX chemotherapy regimen is sufficient to reduce body, lean 
and fat mass (i.e. induce cachexia) and cause malaise, as exhibited by reduced energy expenditure and wheel 
running activity. This study also supports the two main studies in the literature advocating the efficacy of SN co-
supplementation as a therapeutic strategy to mitigate DOX-induced  cardiofibrosis15,16. SN co-supplementation 
protected against a LDM DOX-induced collagen deposition within the heart, whilst not exacerbating the reduc-
tion in end-point body composition indices and muscle/organ mass. SN co-supplementation did not produce a 
beneficial effect, nor was it detrimental at the skeletal muscle level and it was unable to attenuate DOX-induced 
cachexia.
In this study, we were able to induce a progressive form of chemotherapy–induced cachexia with LDM DOX 
administration, as defined by the > 5% reduction in end-point body mass which was driven by reductions in 
both lean and fat  mass51 and was unaffected by SN co-supplementation. The wasting of lean tissue by LDM DOX 
administration was predominately driven by visceral organ (spleen, liver, kidney) mass loss, with no impact on 
hindlimb skeletal muscle mass relative to body weight, albeit hindlimb muscle mass was reduced by DOX com-
mensurate with the loss of body mass. We saw no evidence of muscle fibre atrophy (i.e. fibre CSA) of TA muscles. 
While this finding was unexpected, we postulate that skeletal muscle toxicity (similar to cardiac muscle toxicity) 
Figure 3.  The effect of LDM DOX administration and SN co-supplementation on cardiac muscle histology. (A) 
Heart mass was weighed immediately post-harvest, with DOX + SN treatment reducing heart mass compared 
to VEH (*p < 0.05) and DOX (^p < 0.05) mice. (B) When expressed as a percentage of the final body mass 
(BM), there were no significant differences in heart mass between groups. Gross morphological cardiac muscle 
indices were evaluated from H&E stained sections, measured in triplicate and normalised to (C) total heart 
diameter, which was increased in DOX mice (*p < 0.05) compared to VEH. However, DOX + SN treatment 
had a tendency (p = 0.08) to correct this DOX-induced change back to VEH control levels. (D) Next, we made 
morphological measurements of the cardiac muscle and ventricular lumen components of the lower hear 
(expressed as a percentage of total heart diameter). DOX + SN treatment increased the wall thickness of left 
ventricle (LV) compared to VEH (*p < 0.05) and DOX (^p < 0.05) mice, however, the intraventricular septum 
(IVS) and right ventricular (RV) wall thickness were unchanged from treatments. DOX + SN treatment also 
reduced the diameter of the LV and RV lumen (*p < 0.05 DOX + SN versus VEH and ^p < 0.05 DOX + SN versus 
DOX). (E) Representative images of the H&E sections displayed. (F) Heart sections were also stained using 
Masson’s trichrome to evaluate the relative percentage of collagen/fibrotic connective tissue. DOX-treated mice 
had a greater relative percentage of collagen (*p < 0.05) compared to VEH, while DOX + SN mice corrected this 
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Figure 4.  The effect of LDM DOX administration and SN co-supplementation on skeletal muscle histology. Tibialis anterior 
(TA) muscles were cryosectioned and underwent H&E staining to assess skeletal muscle architecture and fibre cross-sectional 
area (CSA). (A) The relative distribution of fibre size normalized as a percentage of total fibres; and (B) mean muscle fibre 
cross sectional area (CSA); demonstrated no significant differences between groups. Skeletal muscle cross sections also 
underwent (C) Oil Red O (ORO) staining to evaluate lipid content; and (D) Succinate Dehydrogenase (SDH) staining to 
evaluate mitochondrial content. There were no significant effects of treatments on these indices. (E) To assess whether fibre 
types were affected differently by either DOX alone of with SN supplementation, SDH-stained sections were used to determine 
the CSA of isolated oxidative and glycolytic fibre populations. There was no effect of DOX treatment on the CSA of either 
oxidative or glycolytic fibres, however, DOX + SN treatment decreased the mean CSA of glycolytic fibres (*p < 0.05) n = 6–8.
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Figure 5.  The effect of LDM DOX administration and SN co-supplementation on molecular markers of 
oxidative stress and the anti-oxidant response in skeletal muscle. Western blotting experiments were undertaken 
utilizing soleus muscle homogenate. When probing for molecular markers of oxidative stress, there was no 
significant change in (A) 4-HNE protein expression, a marker of lipid peroxidation, between treatment groups, 
but there was a significant increase in (B) nitrotyrosine protein expression, a marker of excessive peroxynitrite 
 (ONOO-) production in DOX and DOX + SN treated mice (*p < 0.05) compared to VEH. There was also a 
significant increase in (C) NRF-2 protein expression, the master regulator of the anti-oxidant response to 
cellular stress, in DOX and DOX + SN treated mice (*p < 0.05) compared to VEH. (D) DJ-1 protein expression 
was probed for as a positive regulator of NRF-2 activation, which was interestingly, shown to increase in DOX 
mice (*p < 0.05) compared to VEH, whilst there was no significant change in DOX + SN treated mice. Negative 
regulators of NRF-2, i.e. (E) Keap-1, (F) phosphorylated  p62ser349 and total p62 (depicted as a ratio of the total), 
were not significantly changed from treatment. Downstream targets of the anti-oxidant response, i.e. (G) 
NQO-1, (H) SOD-1 and (I) HO-1 did not significantly change from treatment. (J) Representative images of the 
antibodies are displayed alongside a representative image of Coomassie Blue used to normalize to total protein 
content. n = 5–8.
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is dose  dependent44 since other studies that utilized a higher cumulative dose of DOX (i.e. 20–30 mg/kg) have 
demonstrated significant skeletal muscle  wasting17–20. Despite the lack of evidence for skeletal muscle wasting/
atrophy in this model, it is still of interest that our model of LDM DOX administration (12 mg/kg; total cumula-
tive dose over 7 days) can have a substantial acute effect on body and lean (visceral) mass i.e. an ~ 9% reduction 
compared to VEH control. This is comparative to a study by Nissinen et al. which utilized a cumulative dose of 
24 mg/kg over 4 weeks and demonstrated similar body and lean mass loss, although evidence of skeletal muscle 
Figure 6.  The effect of LDM DOX administration and SN co-supplementation on molecular markers of 
mitochondrial content in skeletal muscle. Western blotting experiments were undertaken utilizing soleus 
muscle homogenate. (A) CS activity was assessed as a gold standard marker of mitochondrial content. There 
was a trend towards increased CS activity induced by DOX (p = 0.07) but no effect of DOX + SN. Molecular 
indicators of mitochondrial complex protein content were probed for using the (B) OXPHOS cocktail, with 
no significant change in the protein expression of Complex V (CV)—ATP5A, Complex IV (CIV)—MTCO1, 
Complex II (CII)—SDHB and Complex I (CI)—NDUFB8 from treatment groups. However, the protein 
expression of Complex III (CIII)—UQCRC2 displayed a trend to be reduced in DOX mice (p = 0.07) compared 
to VEH, but was significantly reduced in DOX + SN treated mice (*p < 0.05) compared to VEH. Additionally, 
(C) Cytochrome-c (Cyt-c) protein expression, a marker of mitochondrial content, was significantly increased 
in both DOX and DOX + SN mice (*p < 0.05) compared to VEH. To assess mitochondrial remodelling, we also 
probed for a member of the PGC-1 family, i.e. (D) PGC-1β, which was shown to be significantly increased in 
DOX treated mice (*p < 0.05), but was normalised in DOX + SN mice compared to DOX (^p < 0.05) and VEH 
(p > 0.05). As a marker of metabolic stress, we also probed for (E) phosphorylated (i.e. activated) compared 
to total adenosine monophosphate activated protein kinase (AMPK) and showed no effect of DOX treatment 
alone, but a marked increase with DOX + SN treatment compared to VEH (p < 0.05). (F) Representative images 
of the antibodies are displayed alongside a representative image of Coomassie Blue used to normalize to total 
protein content. n = 5–8.
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mass loss was also  observed18 suggesting that skeletal muscle wasting induced from DOX administration is both 
a time and dose dependent event. Supporting this statement is a recent study by Tarpey et al.29, which utilized 
a single MTD injection of DOX (20 mg/kg) with mice culled 72-h post-injection, to demonstrate a significant 
reduction in body mass but no change in the mass or CSA of hindlimb skeletal muscle. Thus, the LDM DOX 
regimen utilised in this study represents a more clinically-relevant rodent model of DOX-induced cachexia in 
being able to induce similar body composition changes, without the severe systemic toxicity associated with the 
single MTD injection  model39. Further improvement to the LDM DOX administration model could involve 
increasing the cumulative dose while administering DOX over both a longer duration, and for multiple LDM 
cycles, to enhance the potential for the effective pre-clinical screening of therapeutics to mitigate the side-effects 
of chronic DOX-induced toxicity.
The regimen of LDM DOX administration used in our study allowed the observation of an acute mild pro-
collagenic cardiomyopathy involving early changes to the overall heart diameter, but with no change to crude 
heart mass. SN co-supplementation elicited a protective effect by preventing the induction of myocardial fibrosis. 
The increase in fibrotic tissue prevalence in the heart is a consistent hallmark of DOX-induced  cardiotoxicity52–56, 
and our data demonstrate this precedes DOX-induced myocardial toxicity. Surprisingly, SN co-supplementation 
increased left ventricular wall thickness compared to both the VEH and DOX control group. We postulate 
that this finding is relative to enhanced left ventricular performance, which has previously been demonstrated 
by Zhu et al., where SN supplemented prior to, and following, the administration of a single MTD bolus of 
DOX, improved left-ventricular ejection fraction and fractional shortening through improved  Ca2+ cycling and 
 contractility15. Interestingly, SN co-supplementation reduced total heart diameter, heart mass and the left and 
right ventricular lumen diameter relative to the DOX control group, which we hypothesise is part of the poten-
tial protective effect of SN co-supplementation during LDM DOX administration. In this regard, maintaining a 
smaller, but more efficient heart may be beneficial for resisting the cardiac fibrosis induced by DOX treatment. 
Indeed, smaller stature humans and animals are thought to be more resistant to cardiovascular disease than 
their taller/larger  counterparts57.
Fatigue and malaise represents a complex interplay between central nervous system drive, mental state and 
physiological function, and with chemotherapy treatment, is further complicated by nausea and a general feeling 
of unwell alongside altered gut function, which impacts macro and micro nutrient intake and  uptake58–60. Chemo-
therapy administration induces chronic and debilitating fatigue, and this manifests physiologically in the skeletal 
muscular system as contractile and mitochondrial dysfunction (reviewed by us  previously25). Thus, “fatigue” in 
the context of the present study likely represents the inability to generate both the mental and cellular energy 
to perform normal skeletal muscle function rather than true physiological fatigue, whereby normal skeletal 
muscle function cannot be durably maintained despite maximal effort. In this study, LDM DOX administration 
reduced voluntary wheel activity and energy expenditure in a synergistic manner, which was not alleviated by 
SN co-supplementation. DOX has previously been shown to impair skeletal muscle function and wheel running 
performance in mice, and this has been associated with mitochondrial dysfunction resulting from changes to the 
redox status of skeletal  muscle17,20,29,61,62. In our study, DOX-induced “fatigue” was associated with a molecular 
marker of increased nitrosative stress (i.e. abundance of proteins with nitrosylated tyrosines), an indicator of 
increased peroxynitrite  (ONOO-) levels. Excess peroxynitrite production can lead to impaired mitochondrial 
energy metabolism via inhibition of glycolysis and depletion of ATP  pools63. Interestingly, SN co-supplemen-
tation did not further exacerbate the DOX-induced increase in nitrotyrosine expression, which was surprising 
given that we have previously demonstrated an escalation of muscle damage when SN was supplemented to an 
already pro-oxidant environment in the dystrophic mdx mouse model of Duchenne Muscular  Dystrophy37. The 
postulated divergence in efficacy of SN co-supplementation between this study and our previous work in the 
mdx mouse is two-fold; with the first being acute versus chronic co-supplementation (i.e. 1 versus 8 weeks in this 
versus our mdx study) which may be protective rather than promotive of oxidative/nitrosative stress. The second 
factor is that the dynamics of the pro-oxidant environment may be influential. Dystrophic muscle is in a chronic 
state of oxidative stress, thus superfluous nitrate promoted excess peroxynitrite formation which exceeded the 
antioxidant buffering capacity, subsequently escalating myopathy. In contrast, LDM DOX administration which 
was metronomic and of reasonably short duration allowed for redox balancing in between doses in this study.
Surprisingly, the LDM regimen of DOX administration utilized in this study did not induce the expected 
increase in lipid peroxidation (a marker of oxidative stress), as indicated by 4-HNE protein expression. There 
have been mixed results in the literature to this effect, with Smuder et al. displaying a striking increase in 4-HNE 
protein expression when mice were culled 24 h post a single 20 mg/kg injection of  DOX23, whereas Gouspillou 
et al. were unable to show changes to 4-HNE protein expression when mice were treated with a cumulative dose 
of DOX, i.e. 40 mg/kg over 12 weeks20. Collectively, these data in conjunction with ours suggest that LDM DOX 
delivery induces hormesis through NRF-2 to protect the muscle from oxidative stress, and that DJ-1, which has 
antioxidant  properties48,49, is central to the hormetic response at the low DOX dose given in our study. In contrast, 
cytotoxic insults (i.e. single bolus MTD DOX treatment) overwhelms endogenous cytoprotective mechanisms 
to induce Phase II antioxidant enzymes such as  SOD23.
We have previously demonstrated that DOX induces mitochondrial toxicity and reduces the mitochondrial 
pool in cultured myoblasts and  myotubes64. In this study, we assessed the mitochondrial content by probing CS 
activity and mitochondrial ETC complex density in SOL and SDH content in TA, mitochondrial toxicity by prob-
ing Cyt-c, as well as the mitochondrial remodelling marker, PGC1β. We saw no change from either LDM DOX 
administration, nor SN co-supplementation, in the mitochondrial content of slow type I SOL muscle or the SDH 
content of whole fast type II TA cross-sections. However, both Cyt-c and PGC1β were elevated by DOX treatment 
highlighting the onset of mitochondrial toxicity and turnover as shown previously following the administra-
tion of various chemotherapeutic agents to human breast cancer cell  lines65. Sanchez-Alcazar et al. have shown 
that increased expression of Cyt-c within the mitochondria and induction of PGC1-mediated mitochondrial 
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biogenesis is an early cytoprotective response to anticancer agents, preceding Cyt-C release into the cytoplasm 
and the induction of  apoptosis65. LDM DOX administration appears sufficient to induce mitochondrial toxicity 
but also turnover to preserve skeletal muscle mass.
Surprisingly, and in contrast to the expression profile of all other mitochondrial ETC complex subunits, we 
observed a reduction in the protein expression of Complex III following DOX treatment (with and without 
SN). The reduction in the Complex III subunit, UQCRC2, was an unexpected finding, as previous studies have 
shown that after a single MTD injection of DOX neither the protein expression of UQCRC2 in permeabilized 
 myofibers62, nor the native protein content of Complex III in isolated mitochondria from skeletal muscle, is 
 altered29. However, we postulate that the reduction in UQCRC2 content from LDM administration and SN co-
supplementation could be a molecular marker of the exercise intolerance shown by DOX-treated mice in our 
activity/calorimetry studies. Others have shown increased UQCRC2 expression in the skeletal muscle of young 
mice exposed to cages with voluntary running  wheels66 and that Complex III activity is reduced in sedentary 
mice compared to mice that have undergone treadmill running-based exercise  training67. Interestingly, humans 
with mutations on the cytochrome b subunit of the Complex III assembly, display exercise intolerance and have 
a reduced protein expression of the UQCRC2 subunit in skeletal  muscle68–71.
NO signalling in skeletal muscle is strongly associated with glucose uptake and utilisation during  contraction72 
which may be beneficial in circumstances such as during DOX administration, where mitochondrial dysfunction, 
damage, toxicity and ROS production escalate and energy production capacity is compromised. We have previ-
ously demonstrated that nitrate supplementation can augment contraction-induced glucose uptake in healthy 
type II skeletal muscles, but rather has a suppressive effect on glucose uptake in the pro-oxidative environment of 
dystrophic mdx type II skeletal  muscles37. While we have not undertaken glucose uptake or contraction studies 
here, the activation (phosphorylation) of AMPK in DOX + SN treated SOL along with the higher RQ derived 
from calorimetry studies during voluntary wheel running activity, suggest a greater dependency on glucose 
metabolism following SN supplementation. Consistent with the known effects of nitrate supplementation on 
muscle fibre type switching from fast glycolytic (i.e. type IIb) to fast oxidative glycolytic (type IIa)  phenotype73, 
we have also demonstrated a reduction in the CSA of glycolytic fibres. These adaptations could be of benefit to 
skeletal muscles long term, particularly in mitigating the contractile dysfunction and higher fatiguability reported 
by others in  mice17,27 and  humans74 following chemotherapy administration.
There were several limitations of our research worthy of mention. Firstly, our study examined the effects of 
LDM DOX administration on skeletal and cardiac muscle in an attempt to generate more clinically-relevant data 
than traditional single bolus MTD DOX administration which is typically given in animal studies to elicit skeletal 
muscle wasting and cardiotoxicity: in hindsight, our study would have benefited greatly from including a MTD 
group treated both with and without SN to contrast the DOX delivery regimens and the efficacy of SN against 
them. Secondly, our choice of limb muscles with different fibre-type profiles makes it difficult to compare and 
contrast our histological data (derived from the predominantly fast type II fibre TA muscle) with our molecular 
data (derived from the predominantly slow type I SOL muscle). TA is a common choice for histological analyses 
in mouse hind limb muscle because it is of sufficient size to rigorously generate fibre size distributions (i.e. to 
count enough (> 250) fibres). We chose SOL for our molecular studies since these centred around mitochondrial 
and oxidation markers which are more pronounced in slow oxidative muscle—we have undertaken CSA analyses 
on oxidative (slow type I) and glycolytic (fast type II) fibre populations and demonstrated no differential effects 
of DOX on specific fibre types though. Thirdly, we used mice aged ~ 6w of age which is prior to complete sexual 
maturation at 8w of age. Therefore, the effects observed on body, lean and fat mass indices may be different at 
this age when mice are still growing, versus in mature adult or aging mice when growth has ceased.
In conclusion, we demonstrate that the LDM DOX chemotherapy regimen is sufficient to induce cachexia 
(lean and fat mass wasting inclusive) and fatigue as characterised by reduced participation in voluntary exer-
cise, which appears to be underlined by oxidative/nitrostative stress. Interestingly, the administration of LDM 
DOX induced mild oxidative stress in skeletal muscle, which subsequently evoked a NRF-2 driven anti-oxidant 
response through DJ-1. SN co-supplementation afforded no protective therapeutic potential alongside the admin-
istration of LDM DOX, but nor did it promote the wasting of lean tissue. Importantly, we have evidence of a 
SN co-supplementation driven cardioprotective effect against DOX-induced collagen deposition, however, the 
therapeutic efficacy of SN as an adjunct during DOX administration still requires further examination.
Methods
Animals. Experimental design and treatments. Six-week old male Balb/c mice were acquired from the Ani-
mal Resource Centre (ARC, Western Australia) and were randomly allocated to treatment groups (n = 8) upon 
arrival. Mice were housed on a 12-h light/dark cycle with ad  libitum access to food i.e. standard mice chow 
and water supply throughout the experiments. Mice were administered with either VEH (0.9% NaCl) or DOX 
(4 mg/kg in 0.9% NaCl; Sigma Aldrich, Australia) via intraperitoneal injection 3 times over a 7 day period (i.e. 
on day 1, 3 and 5; for a cumulative dose of 12 mg/kg) which is the equivalent to a low cumulative clinical  dose5,75, 
thus depicting a model of LDM DOX administration. SN was co-supplemented in drinking water ( 85 mg/L−1 
(1 mM) (Sigma Aldrich, Australia)) throughout the duration of the LDM DOX regimen in a third group of ani-
mals (DOX + SN group). This dose of SN is equivalent to that used previously by us and others, demonstrating 
efficacy to transiently increase plasma and skeletal muscle nitrate  levels37,76. Animals were weighed prior to the 
commencement of treatment (PRE), on each day of treatment and at the experimental endpoint. Food and water 
consumption were monitored throughout the duration of the treatment protocol.
Body composition analyses. Echo Magnetic Resonance Imaging (echoMRI) was utilized to assess the 
effect of DOX and DOX + SN on body composition. Live mice were placed into an echoMRI body composition 
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analyzer (EMR-150, Echo Medical Systems, USA) on day 1 (PRE) and day 8 (POST) of the treatment protocol. 
Total lean and fat mass were quantified via triplicate scans spaced 30 s apart. Data are the delta change in the 
mean of triplicate scans between the PRE and POST testing periods.
indirect calorimetry & activity monitoring. To evaluate the impact of DOX and DOX + DOX + SN on 
the physical and associated metabolic activity of mice, animals were individually housed for 24 h in Promethion 
Metabolic cages (Sable Systems, LV, USA) on day 0–1 (PRE) and day 7–8 (POST). Cages allowed free access to 
food, water and a running wheel. Real-time voluntary activity and whole-body metabolic activity was monitored 
throughout both 24-h periods, with the key variables of wheel running, ambulatory activity (pedestrian meters), 
energy expenditure and the respiratory quotient  (VCO2/VO2) analysed as described by us  previously77. Data 
presented are the total for a circadian cycle (i.e. of the diurnal phase recorded from 7am-7 pm and the nocturnal 
phase recorded from 7 pm-7am) in the PRE and POST periods, or the delta change between the PRE and POST 
periods..
Surgery. At the conclusion of treatment (POST) live analyses, non-recovery surgery was performed on 
animals. Mice were deeply anaesthetised via isoflurane inhalation (5% induction and 2–3% maintenance) and 
non-survival surgery was performed. Tissues of interest were surgically excised, weighed and snap-frozen for 
post-hoc analyses in the following order: (1) SOL muscle was taken for western blotting experiments; and (2) 
TA muscle and heart were taken for histological assessment. Additional tissues of interest harvested were skeletal 
muscles extensor digitorum longus (EDL) and plantaris (PLNT), alongside epididymal and subcutaneous fat, 
spleen, kidney and liver, which were also weighed prior to being snap-frozen.
Histological analyses. Skeletal muscle histology. All histological protocols were performed as described 
by us  previously37,78. To determine whether LDM DOX had atrophic effects on skeletal muscle and subsequently, 
whether DOX + SN either exacerbated or rescued any such atrophy, we next assessed the hindlimb muscle, TA 
histologically. TA muscles were cryopreserved in optimal cutting temperature compound (Sakura Finetek) us-
ing liquid nitrogen-cooled isopentane. TA’s were sectioned (10 µm, -20 °C, Leica CM1950) and mounted. Three 
histological stains were employed to assess various histopathological features. Haematoxylin & Eosin (H&E) was 
utilised to evaluate muscle fibre size and architecture. Oil Red O (ORO) staining evaluated lipid content within 
the whole muscle. Succinate dehydrogenase (SDH) staining was utilized to assess the SDH activity, which is in-
dicative of a more oxidative phenotype and subsequently a marker of both mitochondrial density and fibre-type 
transformation. For H&E, ORO and SDH, slides were imaged on a Zeiss Axio Imager Z2 microscope (Carl Zeiss 
MicroImaging GmbH, Germany) at 20 × magnification, respectively. All images were analysed using ImageJ 
software (NIH, USA).
To evaluate fibre type-specific effects of DOX and DOX + SN treatment, glycolytic and oxidative areas of the 
TA were identified in SDH stained sections and at least 250 fibres were counted for each fibre type (i.e. a total 
of at least 500 fibres per section) in each of those areas. The CSA of these fibres was determined as described by 
us  previously37,78.
cardiac muscle histology. The cardiotoxic effects of DOX are well established, and previous research sug-
gests a therapeutic effect for SN in this regard. Thus, in this study, we also sought to investigate the impact of 
our treatments on the heart. Whole hearts were snap-frozen before being transferred to a 10% neutral buffered 
formalin for 48 h for fixation. Once fixed, serial sections were cut at 10 µm diagonally at the mid-ventricle. 
H&E staining was performed to assess gross changes in cardiac muscle, with morphological indices measured 
including left and right ventricular diameter and thickness as well as interventricular septum  thickness79. Mas-
son’s Trichrome staining was performed to assess collagen/fibrotic connective tissue content. All sections were 
imaged at × 20 using a Zeiss Axio Imager Z2 microscope (Carl Zeiss MicroImaging GmbH, Germany). Masson’s 
trichrome stained sections were quantified using a colour histogram and calculated as a percentage of the total 
heart cross sectional area.
Western blot analyses. All western blotting protocols were performed as previously described by 
 us78,80. Since both DOX and SN are notorious producers of  ROS64,81, we next investigated the effect of DOX 
and DOX + SN treatment on molecular markers of oxidative stress related damage, downstream anti-oxidant 
response targets and mitochondrial content and remodelling/biogenesis. Western blot experiments were per-
formed from frozen SOL homogenates. SOL muscles were homogenized for 20-30 s in ice-cold Western Immu-
noprecipitation Kinase (WIK) buffer (40mMTris, pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5% TritonX-100; 25 mM 
β-glycerophosphate; 25  mM NaF; 1  mM  Na3VO4; 10  μg/ml leupeptin; and 1  mM PMSF). Homogenate was 
centrifuged at 3,500 rpm for 5 min at 4 °C, before the pellet was resuspended and the whole muscle homogenate 
was used for further analysis. Protein concentrations were determined using a sample assay kit (Bio-Rad Labora-
tories, Hercules, CA, USA), to ensure equal loading on the gels. Samples were prepared with equivalent amounts 
of protein (20–40 μg) in Laemmli buffer, heated for 5 min at 95 °C, and subjected to electrophoretic separation 
on 7.5% or 12% SDS-acrylamide gels. The only exception to this was when probing for the Total OXPHOS 
cocktail antibody samples were heated for 5 min at 40 °C, as per supplier recommendations. Following electro-
phoretic separation, proteins were transferred to a polyvinylidene fluoride (PVDF) membrane, blocked with 5% 
not-fat milk powder in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h followed by an overnight 
incubation at 4  °C with primary antibody dissolved in TBST containing either 1% BSA or 3% non-fat milk 
powder. The following antibodies were used: anti-4-HNE (1:1,000; #ab46545, Abcam), Total OXPHOS cock-
tail (1:1,000; #ab110413, Abcam), anti-PGC-1β (1:500; #ab176328, Abcam), anti  AMPKThr172 (1:1,000, #2535, 
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CST, anti-AMPK (1:1,000, #2603, CST), Cyt-c (1:2000; #11940, CST), anti-DJ-1 (1:1,000; #5933, CST), anti-
Keap-1 (1:1,000; # 8047, CST), anti-NQO-1 (1:1,000; #62,262, CST), anti-NRF-2 (1:1,000; #12721, CST), anti-
p62Ser349 (1:1,000; #95697, CST), anti-p62 (1:1,000; #5114, CST), anti-HO-1 (1:1,000; #ADI-SPA-894, Enzo Life 
sciences), anti-SOD-1 (1:2000; #ADI-SOD-101, Enzo Life Sciences) and anti-nitrotyrosine (1:1,000; #06–284, 
Millipore). After overnight incubation, the membranes were washed 3 separate times for 10 min each in TBST 
and then probed with a peroxidase-conjugated secondary antibody (1:5,000; anti-rabbit IgG, Vector Laborato-
ries or 1:20,000; anti-mouse IgG, Vector Laboratories) for 1 h at room temperature. Following another set of 3 
separate washes for 10 min in TBST, the blots were developed with a DARQ CCD camera mounted to a Fusion 
FX imaging system (Vilber Lourmat, Eberhardzell, Germany) using ECL Prime reagent (Amersham, Piscataway, 
NJ, USA). Once the images were captured, the membranes were stained with Coomassie Blue to verify equal 
loading of total protein in all lanes. Densitometric measurements were carried out using FusionCAPTAdvance 
software (Vilber Lourmat).
citrate synthase activity. CS activity was assessed as a marker of mitochondrial content on SOL homoge-
nates prepared for WB analyses and as described by us  previously37,78. Homogenates were added to reagent cock-
tail containing (100 mM TRIS buffer, 1 mM DTNB and 3 mM Acetyl CoA) and oxaloacetate (10 mM) was used 
to initiate the reaction in a plate-based spectrophotometer at 412 nm (25 °C for 5 m). CS activity was calculated 
using the extinction coefficient of 13.682.
Statistics. Data is presented as mean ± standard error of the mean, unless stated otherwise. Data sets were 
tested for normality using a Shapiro–Wilk test. For normal data, a one-way ANOVA with Tukey’s post-Hoc test 
was used to detect treatment differences for all data except for muscle and organ mass and cardiac muscle mor-
phology data where a two-way ANOVA was used with treatment and muscle/organ type/cardiac morphology 
as factors. Where interactions were detected, one-way ANOVA was used for multiple comparisons. Repeated 
measures ANOVA’s were used to assess time-dependent effects on body weight and body composition and vol-
untary activity/calorimetry changes between the PRE and POST periods. An α-value of 0.05 was considered 
significant. Data was analysed using Graphpad prism (GraphPad Software, San Diego, CA 92,108, USA).
ethical approval. All experimental procedures were approved by the Victoria University Animal Ethics 
Committee (AEETH15/006) and conformed to the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes.
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